Detection of alloantibody-mediated complement activation: A diagnostic advance in monitoring kidney transplant rejection?

Clinical Biochemistry

Volumn 49, Issue 4-5, 2016, Pages 394-403

  Böhmig, Georg A ^a   Kikic, Zeljko ^a   Wahrmann, Markus ^a   Eskandary, Farsad ^a   Aliabadi, Arezu Z ^a   Zlabinger, Gerhard J ^b   Regele, Heinz ^a   Feucht, Helmut E ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Fachklinik Bad Heilbrunn   (Germany)

Author keywords

Antibody mediated rejection; C4d; Complement; HLA antibodies; Kidney transplantation; Single antigen beads

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G; ALLOANTIBODY;

ANTIBODY MEDIATED REJECTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; EX VIVO STUDY; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION;

COMPLEMENT ACTIVATION; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION;

EID: 84959470346     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.05.024     Document Type: Article

References (83)

1. Terasaki P.I. Humoral theory of transplantation. Am. J. Transplant. 2003, 3:665-673.
2. Montgomery R.A., Cozzi E., West L.J., Warren D.S. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin. Immunol. 2011, 23:224-234.
3. Smith R.N., Colvin R.B. Chronic alloantibody mediated rejection. Semin. Immunol. 2012, 24:115-121.
4. Valenzuela N.M., McNamara J.T., Reed E.F. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr. Opin. Organ Transplant. 2014, 19:33-40.
5. Cravedi P., Heeger P.S. Complement as a multifaceted modulator of kidney transplant injury. J. Clin. Invest. 2014, 124:2348-2354.
6. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 1969, 280:735-739.
7. Feucht H.E., Schneeberger H., Hillebrand G., Burkhardt K., Weiss M., Riethmüller G., et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 1993, 43:1333-1338.
8. Böhmig G.A., Exner M., Habicht A., Schillinger M., Lang U., Kletzmayr J., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J. Am. Soc. Nephrol. 2002, 13:1091-1099.
9. Cohen D., Colvin R.B., Daha M.R., Drachenberg C.B., Haas M., Nickeleit V., et al. Pros and cons for C4d as a biomarker. Kidney Int. 2012, 81:628-639.
10. Sapir-Pichhadze R., Curra S.P., John R., Tricco A.C., Uleryk E., Laupacis A., et al. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2015, 87:182-194.
11. Stegall M.D., Diwan T., Raghavaiah S., Cornell L.D., Burns J., Dean P.G., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011, 11:2405-2413.
12. Pei R., Wang G., Tarsitani C., Rojo S., Chen T., Takemura S., et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum. Immunol. 1998, 59:313-322.
13. Pei R., Lee J.H., Shih N.J., Chen M., Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003, 75:43-49.
14. Tait B.D., Hudson F., Cantwell L., Brewin G., Holdsworth R., Bennett G., et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009, 14:247-254.
15. Wahrmann M., Exner M., Regele H., Derfler K., Körmöczi G.F., Lhotta K., et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J. Immunol. Methods 2003, 275:149-160.
16. Böhmig G.A., Bartel G., Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr. Opin. Organ Transplant. 2008, 13:411-418.
17. Feucht H.E., Felber E., Gokel M.J., Hillebrand G., Nattermann U., Brockmeyer C., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. 1991, 86:464-470.
18. Feucht H.E., Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int. 1996, 50:1464-1475.
19. Regele H., Böhmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J. Am. Soc. Nephrol. 2002, 13:2371-2380.
20. Behr T.M., Feucht H.E., Richter K., Reiter C., Spes C.H., Pongratz D., et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J. Heart Lung Transplant. 1999, 18:904-912.
21. Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., Williams W.W., Tolkoff-Rubin N., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 1999, 10:2208-2214.
22. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 2001, 12:574-582.
23. Mauiyyedi S., Crespo M., Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J. Am. Soc. Nephrol. 2002, 13:779-787.
24. Herzenberg A.M., Gill J.S., Djurdjev O., Magil A.B. C4d deposition in acute rejection: an independent long-term prognostic factor. J. Am. Soc. Nephrol. 2002, 13:234-241.
25. Nickeleit V., Zeiler M., Gudat F., Thiel G., Mihatsch M.J. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J. Am. Soc. Nephrol. 2002, 13:242-251.
26. Nadasdy G.M., Bott C., Cowden D., Pelletier R., Ferguson R., Nadasdy T. Comparative study for the detection of peritubular capillary C4d deposition in human renal allografts using different methodologies. Hum. Pathol. 2005, 36:1178-1185.
27. Troxell M.L., Weintraub L.A., Higgins J.P., Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin. J. Am. Soc. Nephrol. 2006, 1:583-591.
28. Seemayer C.A., Gaspert A., Nickeleit V., Mihatsch M.J. C4d staining of renal allograft biopsies: a comparative analysis of different staining techniques. Nephrol. Dial. Transplant. 2007, 22:568-576.
29. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 2003, 3:708-714.
30. Sis B., Mengel M., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am. J. Transplant. 2010, 10:464-471.
31. Halloran P.F., de Freitas D.G., Einecke G., Famulski K.S., Hidalgo L.G., Menge L.M., et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am. J. Transplant. 2010, 10:2223-2230.
32. Haas M., Sis B., Racusen L.C., Solez K., Glotz D., Colvin R.B., et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014, 14:272-283.
33. Sis B., Halloran P.F. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr. Opin. Organ Transplant. 2010, 15:42-48.
34. Loupy A., Hill G.S., Suberbielle C., Charron D., Anglicheau D., Zuber J., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am. J. Transplant. 2011, 11:56-65.
35. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr. Opin. Organ Transplant. 2013, 18:319-326.
36. Regele H., Exner M., Watschinger B., Wenter C., Wahrmann M., Österreicher C., et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol. Dial. Transplant. 2001, 16:2058-2066.
37. Kikic Z., Kozakowski N., Oberbauer R., Regele H., Bond G., et al. Capillary C4 and kidney allograft outcome in relation to morphological lesions suggestive of antibody-mediated rejection. Clin. J. Am. Soc. Nephrol. 2015, (in press).
38. Haas M., Rahman M.H., Racusen L.C., Kraus E.S., Bagnasco S.M., Segev D.L., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am. J. Transplant. 2006, 6:1829-1840.
39. Haas M., Segev D.L., Racusen L.C., Bagnasco S.M., Locke J.E., Warren D.S., et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J. Am. Soc. Nephrol. 2009, 20:197-204.
40. Rose M.L., West L.J. Accommodation: does it apply to human leukocyte antigens?. Transplantation 2012, 93:244-246.
41. Iwasaki K., Miwa Y., Ogawa H., Yazaki S., Iwamoto M., Furusawa T., et al. Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction: implication of accommodation. Transplantation 2012, 93:390-397.
42. Kikic Z., Regele H., Nordmeyer V., Wahrmann M., Kletzmayr J., Bartel G., et al. Significance of peritubular capillary, glomerular, and arteriolar C4d Staining patterns in paraffin sections of early kidney transplant biopsies. Transplantation 2011, 91:440-446.
43. Kikic Z., Kozakowski N., Regele H., Priessner K., Nordmeyer V., Marinova L., et al. Clinicopathological relevance of granular C4d deposition in peritubular capillaries of kidney allografts. Transpl. Int. 2014, 27:312-321.
44. Zwirner J., Felber E., Reiter C., Riethmuller G., Feucht H.E. Deposition of complement activation products on plastic-adsorbed immunoglobulins. A simple ELISA technique for the detection of defined complement deficiencies. J. Immunol. Methods 1989, 124:121-129.
45. Lederer S.R., Schneeberger H., Albert E., Johnson J.P., Gruber R., Land W., et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 1996, 61:313-319.
46. Gebel H.M., Liwski R.S., Bray R.A. Technical aspects of HLA antibody testing. Curr. Opin. Organ Transplant. 2013, 18:455-462.
47. Tait B.D., Susal C., Gebel H.M., Nickerson P.W., Zachary A.A., Claas F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95:19-47.
48. Everly M.J., Rebellato L.M., Haisch C.E., Briley K.P., Bolin P., Kendrick W.T., et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 2014, 97:494-501.
49. Schwaiger E., Wahrmann M., Bond G., Eskandary F., Böhmig G.A. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014, 97:1279-1285.
50. Schaub S., Hönger G., Koller M.T., Liwski R., Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014, 98:387-393.
51. Smith J.D., Hamour I.M., Banner N.R., Rose M.L. C4d fixing, Luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am. J. Transplant. 2007, 7:2809-2815.
52. Wahrmann M., Bartel G., Exner M., Regele H., Körmöczi G.F., Fischer G.F., et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl. Int. 2009, 22:982-989.
53. Lachmann N., Todorova K., Schulze H., Schönemann C. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013, 95:694-700.
54. Chen G., Sequeira F., Tyan D.B. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum. Immunol. 2011, 72:849-858.
55. Otten H.G., Verhaar M.C., Borst H.P., Hene R.J., van Zuilen A.D. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am. J. Transplant. 2012, 12:1618-1623.
56. Zeevi A., Lunz J., Feingold B., Shullo M., Bermudez C., Teuteberg J., et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J. Heart Lung Transplant. 2013, 32:98-105.
57. Freitas M.C., Rebellato L.M., Ozawa M., Nguyen A., Sasaki N., Everly M., et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013, 95:1113-1119.
58. Crespo M., Torio A., Mas V., Redondo D., Perez-Saez M.J., Mir M., et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?. Transpl. Immunol. 2013, 29:28-33.
59. Loupy A., Lefaucheur C., Vernerey D., Prugger C., Duong van Huyen J.P., Mooney N., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 2013, 369:1215-1226.
60. Sutherland S.M., Chen G., Sequeira F.A., Lou C.D., Alexander S.R., Tyan D.B. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr. Transplant. 2012, 16:12-17.
61. Visentin J., Vigata M., Daburon S., Contin-Bordes C., Fremeaux-Bacchi V., Dromer C., et al. Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation 2014, 98:625-631.
62. Bartel G., Wahrmann M., Exner M., Regele H., Schillinger M., Hörl W.H., et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007, 83:727-733.
63. Schnaidt M., Weinstock C., Jurisic M., Schmid-Horch B., Ender A., Wernet D. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011, 92:510-515.
64. Kosmoliaptsis V., Bradley J.A., Peacock S., Chaudhry A.N., Taylor C.J. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009, 87:813-820.
65. Cai J., Terasaki P.I., Anderson N., Lachmann N., Schonemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 2009, 88:226-230.
66. Pereira S., Perkins S., Lee J.H., Shumway W., LeFor W., Lopez-Cepero M., et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?. Hum. Immunol. 2011, 72:492-498.
67. Peacock S., Kosmoliaptsis V., Bradley A.J., Taylor C.J. Questioning the added value of Luminex single antigen beads to detect C1q binding donor HLA-specific antibodies. Transplantation 2014, 98:384-386.
68. Amico P., Honger G., Steiger J., Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr. Opin. Organ Transplant. 2009, 14:656-661.
69. Ferrari P., Weimar W., Johnson R.J., Lim W.H., Tinckam K.J. Kidney paired donation: principles, protocols and programs. Nephrol. Dial. Transplant. 2014, (in press).
70. Vaidya S., Partlow D., Susskind B., Noor M., Barnes T., Gugliuzza K. Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead Luminex assay. Transplantation 2006, 82:1524-1528.
71. Wahrmann M., Hlavin G., Fischer G., Marinova L., Schwaiger E., Hörl W.H., et al. Modified solid-phase alloantibody detection for improved crossmatch prediction. Hum. Immunol. 2013, 74:32-40.
72. Böhmig G.A., Fidler S., Christiansen F.T., Fischer G., Ferrari P. Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. Hum. Immunol. 2013, 74:500-505.
73. Le Bas-Bernardet S., Hourmant M., Valentin N., Paitier C., Giral-Classe M., Curry S., et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 2003, 75:477-482.
74. Eng H.S., Bennett G., Bardy P., Coghlan P., Russ G.R., Coates P.T. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum. Immunol. 2009, 70:595-599.
75. Bearden C.M., Agarwal A., Book B.K., Sidner R.A., Gebel H.M., Bray R.A., et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum. Immunol. 2004, 65:803-809.
76. Wahrmann M., Exner M., Haidbauer B., Schillinger M., Regele H., Körmöczi G., et al. [C4d]FlowPRA screening-a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum. Immunol. 2005, 66:526-534.
77. Mohan S., Palanisamy A., Tsapepas D., Tanriover B., Crew R.J., Dube G., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J. Am. Soc. Nephrol. 2012, 23:2061-2071.
78. Hönger G., Wahrmann M., Amico P., Hopfer H., Böhmig G.A., Schaub S. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010, 89:1471-1475.
79. Bartel G., Wahrmann M., Schwaiger E., Kikic Z., Winzer C., Horl W.H., et al. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl. Int. 2012, 26:121-130.
80. Lawrence C., Willicombe M., Brookes P.A., Santos-Nunez E., Bajaj R., Cook T., et al. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 2013, 95:341-346.
81. Bartel G., Wahrmann M., Exner M., Regele H., Huttary N., Schillinger M., et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am. J. Transplant. 2008, 8:41-49.
82. Sicard A., Ducreux S., Rabeyrin M., Couzi L., McGregor B., Badet L., et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J. Am. Soc. Nephrol. 2015, 26:457-467.
83. Yabu J.M., Higgins J.P., Chen G., Sequeira F., Busque S., Tyan D.B. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011, 91:342-347.